Identification of (R)-1-(5-tert-butyl-2,3-dihydro-1H-inden-1-yl)-3-(1H- indazol-4-yl)urea (ABT-102) as a potent TRPV1 antagonist for pain management

Journal of Medicinal Chemistry

Volumn 51, Issue 3, 2008, Pages 392-395

  Gomtsyan, Arthur ^a   Bayburt, Erol K ^a   Schmidt, Robert G ^a   Surowy, Carol S ^a   Honore, Prisca ^a   Marsh, Kennan C ^a   Hannick, Steven M ^a   McDonald, Heath A ^a   Wetter, Jill M ^a   Sullivan, James P ^a   Jarvis, Michael F ^a   Faltynek, Connie R ^a   Lee, Chih Hung ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; ABT 102; UNCLASSIFIED DRUG; UREA DERIVATIVE; VANILLOID RECEPTOR 1;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG POTENCY; DRUG SOLUBILITY; DRUG STRUCTURE; IC 50; NONHUMAN; PAIN; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANALGESICS; ANIMALS; BIOLOGICAL AVAILABILITY; DOGS; HAPLORHINI; HUMANS; INDAZOLES; INDENES; MICROSOMES, LIVER; PAIN; RATS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRPV CATION CHANNELS; UREA;

EID: 39149117718     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm701007g     Document Type: Article

References (22)

1. Nilius, B.; Owsianik, G.; Voets, T.; Peters, J. A. Transient receptor potential cation channels in disease. Physiol. Rev. 2007, 87, 165-217.
2. Szallasi, A.; Cortright, D. N.; Blum, C. A.; Eid, S. R. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat. Rev. Drug Discovery 2007, 6, 357-372.
3. Caterina, M. J.; Schumacher, M. A.; Tominaga, M.; Rosen, T. A.; Levine, J. D.; Julius, D. The capsaicin receptor: A heat-activated ion channel in the pain pathway. Nature 1997, 389, 816-824.
4. Caterina, M. J.; Julius, D. The vanilloid receptor: A molecular gateway to the pain pathway. Annu. Rev. Neurosci. 2001, 24, 487-517.
5. Geppetti, P.; Trevisani, M. Activation and sensitization of the vanilloid receptor: role in gastrointestinal inflammation and function. Br. J. Pharmacol. 2004, 141, 1313-1320.
6. Bley, K. R. Recent developments in transient receptor potential vanilloid receptor 1 agonist-based therapies. Expert Opin. Invest. Drugs 2004, 13, 1445-1456.
7. Westaway, S. M. The potential of transient receptor potential vanilloid type 1 channel modulators for the treatment of pain. J. Med. Chem. 2007, 50, 2589-2596.
8. Szallasi, A.; Cruz, F.; Geppetti, P. TRPV1: A therapeutic target for novel analgesic drugs. Trends Mol. Med. 2006, 12, 545-554.
9. Cui, M.; Honore, P.; Zhong, C.; Gauvin, D.; Mikusa, J.; Hernandez, G.; Chandran, P.; Gomtsyan, A.; Brown, B.; Bayburt, E. K.; Marsh, K.; Bianchi, B.; McDonald, H.; Niforatos, W.; Neelands, T. R.; Decker, M. W.; Lee, C.-H.; Sullivan, J. P.; Faltynek, C. R. TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists. J. Neurosci. 2006, 26, 9385-9393.
10. Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.; Perner, R. J.; Didomenico, S.; Koenig, J. R.; Turner, S.; Jinkerson, T.; Drizin, I.; Hannick, S. M.; Macri, B. S.; Mcdonald, H. A.; Honore, P.; Wismer, C. T.; Marsh, K. C.; Wetter, J.; Stewart, K. D.; Oie, T.; Jarvis, M. F.; Surowy, C. S.; Faltynek, C. R.; Lee, C.-H. Novel transient potential vanilloid 1 receptor antagonists forthetreatmentofpain: Structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J. Med. Chem. 2005, 48, 744-752.
11. El Kouhen, R.; Surowy, C. S.; Bianchi, B. R.; Neelands, T. R.; Mcdonald, H. A.; Niforatos, W.; Gomtsyan, A.; Lee, C.-H.; Honore, P.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R. A-425619 [1-Isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J. Pharmacol. Exp. Ther. 2005, 314, 400-409.
12. Honore, P.; Wismer, C. T.; Mikusa, J.; Zhu, C. Z.; Zhong, C.; Gauvin, D. M.; Gomtsyan, A.; El Kouhen, R.; Lee, C-H.; Marsh, K. C.; Sullivan, J. P.; Faltynek, C. R.; Jarvis, M. F. A-425619 [1-isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J. Pharmacol. Exp. Ther. 2005, 314, 410-421.
13. Gomtsyan, A.; Bayburt, E. K.; Keddy, R.; Turner, S. C.; Jinkerson, T. K.; Didomenico, S.; Perner, R. J.; Koenig, J. R.; Koenig; McDonald, H. A.; Surowy, C. S.; Honore, P.; Mikusa, J.; Marsh, K. C.; Wetter, J. M.; Faltynek, C. R.; Lee, C.-H. α-Methylation at benzylic fragment of N-aryl-N′-benzyl ureas provide TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model. Bioorg. Med. Chem. Lett. 2007, 17, 3894-3899.
14. Drizin, I.; Gomtsyan, A.; Bayburt, E. K.; Schmidt, R. G.; Zheng, G. Z.; Perner, R. J.; Didomenico, S.; Koenig, J. R.; Turner, S. C.; Jinkerson, T. K.; Brown, B. S.; Keddy, R. G.; McDonald, H. A.; Honore, P.; Wismer, C. T.; Marsh, K. C.; Wetter, J. M.; Polakowski, J. S.; Segreti, J. A.; Jarvis, M. F.; Faltynek, C. R.; Lee, C.-H. Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists. Bioorg. Med. Chem. 2006, 14, 4740-4749.
15. Doherty, E. M.; Fotsch, C.; Bo, Y.; Chakrabarti, P. P.; Chen, N.; Gavva, N.; Han, N.; Kelly, M. G.; Kincaid, J.; Klionsky, L.; Liu, Q.; Ognyanov, V. I.; Tamir, R.; Wang, X.; Zhu, J.; Norman, M. H.; Treanor, J. J. S. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J. Med. Chem. 2005, 48, 71-90.
16. Cannon, J. G.; Perez, J. A.; Bhatnagar, R. K.; Long, J. P.; Sharabi, F. M. Conformationally restricted congeners of dopamine derived from 2-aminoindan. J. Med. Chem. 1982, 25, 1442-1446.
17. Smith, H. E.; Willis, T. C. Optical rotatory dispersion and circular dichroism of the N-salicylidene derivatives of α- and β-phenylalkylamines - The absolute configurations of some phenylnorbornanes. Tetrahedron 1970, 26, 107-118.
18. For a large-scale asymmetric synthesis of ABT-102, see Lukin, K.; Chambournier, G.; Kotecki, B.; Venkatramani, C. J.; Leanna, M. R. Development of a large-scale asymmetric synthesis of vanilloid receptor (TRPV1) antagonist ABT-102. Org. Proc. Res. Dev. 2007, 11, 578-584.
19. Surowy C. S.; Neelands T. R.; Bianchi B. R.; McGaraughty S.; Chu K.; McDonald H. A.; El-Kouhen R.; Han P.; Vos M.; Niforatos W.; Lee C.-H.; Gomtsyan A.; Honore P.; Sullivan J. P.; Jarvis M. F.; Faltynek C. R. ABT-102 (1-((R)-5-tert-butyl-indan-1-yl)-3-(1H-indazol-4-yl)-urea) blocks polymodal activation of TRPV1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. Submitted for publication.
20. Honore P.; Chandran, P.; Hernandez, G.; Gauvin, D. M.; Mikusa, J. P.; Zhong, C.; Ghilardi, J. R.; Sevcik, M. A.; Fryer, R. M.; Segreti, J. A.; Banfor, P. N.; Widomski, D. L.; Reinhart, G.; Marsh, K.; Neelands, T.; Niforatos, W.; McDonald H.; Bayburt, E. K.; Daanen, J. F.; Gomtsyan, A.; Lee, C.-H.; Surowy, C.; Mantyh, P. W.; Sullivan, J. P.; Jarvis, M. F.; Faltynek, C. R. Repeated dosing of ABT-102, a potent and selective TRPV1 antagonist, enhances TRPV1-mediated analgesic activity in rodents, but attenuates antagonist-induced hyperthermia. Submitted for publication.
21. Gavva, N. R.; Bannon, A. W.; Surapaneni, S.; Hovland, D. N., Jr.; Lehto, S. G.; Gore, A.; Juan, T.; Deng, H.; Han, B.; Klionsky, L.; Kuang, R.; Le, A.; Tamir, R.; Wang, J.; Youngblood, B.; Zhu, D.; Norman, M. H.; Magal, E.; Treanor, J. J. S.; Louis, J-C. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J. Neurosci. 2007, 27, 3366-3374.
22. Gavva, N. R.; Bannon, A. W.; Hovland, D. N., Jr.; Lehto, S. G.; Klionsky, L.; Surapaneni, S.; Immke, D. C.; Henley, C.; Arik, L.; Bak, A.; Davis, J.; Ernst, N.; Hever, G.; Kuang, R.; Shi, L.; Tamir, R.; Wang, J.; Wang, W.; Zajic, G.; Zhu, D.; Norman, M. H.; Louis, J-C.; Magal, E.; Treanor, J. J. S. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J. Pharmacol. Exp. Ther. 2007, 323, 128-137.